Literature DB >> 34061004

Lack of Association Between Recent Cannabis Use and Advanced Liver Fibrosis Among HIV-positive Heavy Drinkers.

Daniel Fuster1, Kaku So-Armah2, Debbie M Cheng3, Sharon M Coleman4, Natalia Gnatienko5, Dmitry Lioznov6, Evgeny M Krupitsky7, Matthew S Freiberg8, Jeffrey H Samet9.   

Abstract

AIM: This study aimed to analyze the association between any past-month cannabis use and advanced liver fibrosis.
BACKGROUND: Cannabinoid receptors play a role in acute and chronic liver injury, but human studies addressing the impact of cannabis use on liver fibrosis have shown mixed results.
OBJECTIVE: The objective of this study was to explore and estimate the association between pastmonth cannabis use and advanced liver fibrosis (ALF) in a cohort of Russian HIV-positive individuals with heavy alcohol use and a high prevalence of hepatitis C virus (HCV) coinfection.
METHODS: Baseline data were analyzed from participants of the ZINC study, a trial that enrolled HIV-positive Russian patients without prior antiretroviral therapy. Cannabis use during the prior month was assessed at study entry. ALF was defined as FIB-4>3.25 and APRI>1.5. Transient elastography was used to detect advanced liver fibrosis among participants with FIB-4 values in the intermediate range (between 1.45 and 3.25).
RESULTS: Participants (n=248) were mostly male (72.6%), young (median age of 33.9 years), infected with HCV (87.9%), and did not have advanced immunosuppression (median CD4 count 465). Cannabis use was uncommon (12.4%), and the prevalence of advanced liver disease was 21.7%. The prevalence of ALF was similar among those who used cannabis compared to those who did not (25.8% vs. 21.7%). We were unable to detect an association between cannabis use and ALF (adjusted odds ratio: 1.28, 95% confidence interval: 0.53-3.12, p=0.59) in logistic regression models adjusting for age, sex, heavy drinking, BMI, and CD4 cell count.
CONCLUSION: In this exploratory study among HIV-positive heavy drinking Russians, we did not detect an association between recent cannabis use and ALF. Larger scale studies, including more participants with cannabis use, are needed to examine this relationship further. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Cannabis; FIB-4.; HCV; HIV; alcohol; liver fibrosis

Mesh:

Year:  2021        PMID: 34061004      PMCID: PMC8597417          DOI: 10.2174/1570162X19666210519151320

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.341


  72 in total

1.  Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment.

Authors:  Mikkel Arendt; Povl Munk-Jørgensen; Leo Sher; Signe O W Jensen
Journal:  Drug Alcohol Depend       Date:  2010-10-25       Impact factor: 4.492

2.  Progression of liver fibrosis among injection drug users with chronic hepatitis C.

Authors:  Lucy E Wilson; Michael Torbenson; Jacquie Astemborski; Hawazin Faruki; Charles Spoler; Rudra Rai; Shruti Mehta; Gregory D Kirk; Kenrad Nelson; Nezam Afdhal; David L Thomas
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

3.  Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities.

Authors:  Benedikt Fischer; Sameer Imtiaz; Katherine Rudzinski; Jürgen Rehm
Journal:  J Public Health (Oxf)       Date:  2015-01-28       Impact factor: 2.341

4.  Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.

Authors:  Vasily Isakov; Vladimir Chulanov; Dzhamal Abdurakhmanov; Eduard Burnevich; Elena Nurmukhametova; Galina Kozhevnikova; Natalya Gankina; Sergey Zhuravel; Svetlana Romanova; Robert H Hyland; Sophia Lu; Evguenia S Svarovskaia; John McNally; Diana M Brainard; Vladimir Ivashkin; Vyacheslav Morozov; Igor Bakulin; Martin Lagging; Konstantin Zhdanov; Ola Weiland
Journal:  Infect Dis (Lond)       Date:  2018-11-30

Review 5.  Non-invasive diagnosis and biomarkers in alcohol-related liver disease.

Authors:  Christophe Moreno; Sebastian Mueller; Gyongyi Szabo
Journal:  J Hepatol       Date:  2019-02       Impact factor: 25.083

6.  Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study.

Authors:  Tekeda F Ferguson; Erika Rosen; Rotonya Carr; Meghan Brashear; Liz Simon; Katherine P Theall; Martin J Ronis; David A Welsh; Patricia E Molina
Journal:  Alcohol Alcohol       Date:  2020-02-07       Impact factor: 2.826

7.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Authors:  Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

Review 8.  Global epidemiology of hepatitis C virus infection.

Authors:  Colin W Shepard; Lyn Finelli; Miriam J Alter
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

9.  Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.

Authors:  Juan Berenguer; Julio Alvarez-Pellicer; Pilar Miralles Martín; José López-Aldeguer; Miguel Angel Von-Wichmann; Carmen Quereda; Josep Mallolas; José Sanz; Cristina Tural; José María Bellón; Juan González-García
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

10.  Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.

Authors:  Christophe Hézode; Elie Serge Zafrani; Françoise Roudot-Thoraval; Charlotte Costentin; Ali Hessami; Magali Bouvier-Alias; Fatiha Medkour; Jean-Michel Pawlostky; Sophie Lotersztajn; Ariane Mallat
Journal:  Gastroenterology       Date:  2007-11-28       Impact factor: 22.682

View more
  1 in total

Review 1.  Cannabinoids and Chronic Liver Diseases.

Authors:  Ralph-Sydney Mboumba Bouassa; Giada Sebastiani; Vincenzo Di Marzo; Mohammad-Ali Jenabian; Cecilia T Costiniuk
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.